+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Comments

Loading...

Barinthus Biotherapeutics

BRNSNASDAQ

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$1.45

0.053.21%

At Close: -

$1.47

0.021.73%

After Hours: Jul 18, 8:28 AM EDT

15 minutes delayed

Barinthus Biotherapeutics (BRNS) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Barinthus Biotherapeutics (NASDAQ:BRNS) Stock

Barinthus Biotherapeutics Stock (NASDAQ: BRNS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, June 21, 2024

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Avi Kapoor

Thursday, June 13, 2024

Barclays Maintains Overweight on Barinthus Bi...
Benzinga Newsdesk

Wednesday, June 12, 2024

Barinthus Bio To Prioritize Development Of VT...
Benzinga Newsdesk

Friday, June 07, 2024

HC Wainwright & Co. Reiterates Buy on Barinth...
Benzinga Newsdesk

Wednesday, June 05, 2024

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights

Wednesday, May 22, 2024

Barinthus Bio To Present VTP-300 Clinical Upd...
Benzinga Newsdesk

Thursday, May 16, 2024

HC Wainwright & Co. Reiterates Buy on Barinth...
Benzinga Newsdesk

Monday, May 13, 2024

Barinthus Biotherapeutics Q1 EPS $(0.40) Beat...
Benzinga Newsdesk

Wednesday, May 01, 2024

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights

Tuesday, April 30, 2024

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights

Monday, April 22, 2024

HC Wainwright & Co. Reiterates Buy on Barinth...
Benzinga Newsdesk

Friday, April 19, 2024

HC Wainwright & Co. Reiterates Buy on Barinth...
Benzinga Newsdesk
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
Vandana Singh

Thursday, April 18, 2024

Barinthus Bio Announces Topline Data From Pha...
Benzinga Newsdesk

Thursday, April 04, 2024

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights

Wednesday, April 03, 2024

12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights

Thursday, March 21, 2024

HC Wainwright & Co. Maintains Buy on Barinthu...
Benzinga Newsdesk

Wednesday, March 20, 2024

Barinthus Biotherapeutics: Q4 Earnings Insights
Benzinga Insights

Tuesday, March 19, 2024

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Zacks

Monday, February 19, 2024

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights

Thursday, December 21, 2023

Barinthus Biotherapeutics Collaborates With C...
Benzinga Newsdesk

Tuesday, November 28, 2023

HC Wainwright & Co. Reiterates Buy on Barinth...
Benzinga Newsdesk

Thursday, November 09, 2023

Barinthus Biotherapeutics Q3 EPS $(0.37) Down...
Benzinga Newsdesk
Barinthus Bio Said Initial Data From The Combination Of Imdusiran And VTP-300 Show Meaningful Reductions Of HBsAg Levels That Were Maintained Well Below Baseline.
Charles Gross

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved